Inhibikase Therapeutics, Inc. short interest in 2022
In 2022, Inhibikase Therapeutics, Inc.'s disclosed short interest ran from 0.76% of shares outstanding on 14 Jan 2022 to 0.75% on 30 Dec 2022, a change of -0.01 percentage points. The year's high was 0.78% on 31 Mar 2022 and its low 0.24% on 15 Aug 2022, averaging 0.55% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 2.72 days on 14 Apr 2022. Full history: Inhibikase Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 0.76% (14 Jan 2022)
- End of year
- 0.75% (30 Dec 2022)
- Change
- -0.01 pp
- High
- 0.78% (31 Mar 2022)
- Low
- 0.24% (15 Aug 2022)
- Average
- 0.55%
- Highest days to cover
- 2.72 (14 Apr 2022)
- SEC filings marked
- 5
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 0.76% | 1.00 | |
| 31 Jan 2022 | 0.64% | 1.09 | |
| 15 Feb 2022 | 0.50% | 1.99 | |
| 28 Feb 2022 | 0.61% | 1.37 | |
| 15 Mar 2022 | 0.76% | 1.59 | |
| 31 Mar 2022 | 0.78% | 2.65 | 10-K filed |
| 14 Apr 2022 | 0.62% | 2.72 | |
| 29 Apr 2022 | 0.41% | 1.09 | |
| 13 May 2022 | 0.39% | 1.00 | |
| 31 May 2022 | 0.67% | 1.02 | 10-Q filed |
| 15 Jun 2022 | 0.35% | 1.00 | |
| 30 Jun 2022 | 0.38% | 1.42 | |
| 15 Jul 2022 | 0.40% | 2.46 | |
| 29 Jul 2022 | 0.31% | 1.77 | |
| 15 Aug 2022 | 0.24% | 1.00 | 10-Q filed |
| 15 Nov 2022 | 0.78% | 1.00 | 10-Q filed |
| 30 Nov 2022 | 0.56% | 2.05 | results (8-K) |
| 15 Dec 2022 | 0.54% | 2.45 | |
| 30 Dec 2022 | 0.75% | 1.93 |
See also: Inhibikase Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.